Searchable abstracts of presentations at key conferences in endocrinology

ea0019p85 | Clinical practice/governance and case reports | SFEBES2009

Assessing the impact of a fracture liaison service: a comparative audit of secondary prevention of osteoporosis in post-menopausal females treated in two fracture units, one with a fracture liaison service and one without

Callachand F , Wallace I , Elliott J , Gardiner P

Background: Osteoporosis leads to significant morbidity and disability through an increased susceptibility to fracture. Post-menopausal females are a high-risk group. A fracture liaison service model has been proposed as a method to maximise initiation of treatment for secondary prevention following a fragility fracture.Aim: To compare practice in two fracture units to guidelines contained in the National Institute for Clinical Excellence (NICE) Technolo...

ea0019p331 | Steroids | SFEBES2009

A case of triple A syndrome: more than just glucocorticoid deficiency

Wallace I , Hunter S , Koehler K , Huebner A , Carson D

Triple A syndrome (also known as Allgrove’s syndrome, MIM #231550) is a rare autosomal recessive disorder characterised by ACTH-resistant adrenal insufficiency, alacrima and achalasia. Neurological features may also be present. Various combinations of these features may be present which evolve over time. Triple A syndrome is caused by mutations in the AAAS gene which encodes for the protein ALADIN, a member of the nuclear pore complex, whose function is incompletely under...

ea0019p279 | Pituitary | SFEBES2009

Macroprolactinaemia: what is the long-term prognosis? Results from an original series of 55 patients after 10 years clinical follow-up

Wallace I , Satti N , Courtney H , Leslie H , Bell P , Hunter S , McCance D , Sheridan B , Atkinson A

Macroprolactinaemia is defined as hyperprolactinaemia with a predominance of macroprolactin. It is present in approx 15–36% of cases of hyperprolactinaemia. Controversy exists as to the clinical relevance of macroprolactinaemia with a number of short-term studies demonstrating fewer classical symptoms of hyperprolactinaemia. The long-term prognosis is unknown.We have previously reported the findings after 5 years follow-up of a cohort of 55 patients...